AU2019413421B9 - Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound - Google Patents

Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound Download PDF

Info

Publication number
AU2019413421B9
AU2019413421B9 AU2019413421A AU2019413421A AU2019413421B9 AU 2019413421 B9 AU2019413421 B9 AU 2019413421B9 AU 2019413421 A AU2019413421 A AU 2019413421A AU 2019413421 A AU2019413421 A AU 2019413421A AU 2019413421 B9 AU2019413421 B9 AU 2019413421B9
Authority
AU
Australia
Prior art keywords
compound
pharmaceutical composition
mixture
sodium
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019413421A
Other languages
English (en)
Other versions
AU2019413421B2 (en
AU2019413421A1 (en
Inventor
Jingjing Chen
Jun Dai
Zhulian JIANG
Lingling JIN
Chen Li
Qide Li
Qingxia LI
Jundong LIU
Yanqing SUN
Dong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AU2019413421A1 publication Critical patent/AU2019413421A1/en
Publication of AU2019413421B2 publication Critical patent/AU2019413421B2/en
Application granted granted Critical
Publication of AU2019413421B9 publication Critical patent/AU2019413421B9/en
Assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. reassignment CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Request for Assignment Assignors: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., Shouyao Holdings (beijing) Co., Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019413421A 2018-12-24 2019-12-24 Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound Active AU2019413421B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811581815.8 2018-12-24
CN201811581815 2018-12-24
CN201910679429 2019-07-26
CN201910679429.0 2019-07-26
PCT/CN2019/127837 WO2020135401A1 (zh) 2018-12-24 2019-12-24 吡咯并嘧啶化合物的治疗用途及其固体药物组合物

Publications (3)

Publication Number Publication Date
AU2019413421A1 AU2019413421A1 (en) 2021-08-12
AU2019413421B2 AU2019413421B2 (en) 2025-02-13
AU2019413421B9 true AU2019413421B9 (en) 2025-02-20

Family

ID=71126879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019413421A Active AU2019413421B9 (en) 2018-12-24 2019-12-24 Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Country Status (8)

Country Link
US (1) US20220072002A1 (enExample)
EP (1) EP3904356A4 (enExample)
JP (2) JP2022515272A (enExample)
KR (1) KR20210132007A (enExample)
CN (2) CN113242859B (enExample)
AU (1) AU2019413421B9 (enExample)
CA (1) CA3123985A1 (enExample)
WO (1) WO2020135401A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物
CN118973582A (zh) * 2022-03-21 2024-11-15 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024153148A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种杂环化合物、药物组合物及其用途
WO2024230727A1 (zh) * 2023-05-09 2024-11-14 正大天晴药业集团股份有限公司 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235819A1 (en) * 2014-12-16 2017-10-25 Centaurus BioPharma Co., Ltd. Pyrrolopyrimidine compound
WO2017215628A1 (zh) * 2016-06-16 2017-12-21 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775204A1 (en) * 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
US20050130302A1 (en) * 2003-09-29 2005-06-16 Reprocell Inc. Method and composition for regulating expansion of stem cells
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
KR101566840B1 (ko) * 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
AR076794A1 (es) * 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3354652B1 (en) * 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PH12013502523A1 (en) * 2011-06-14 2019-10-11 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
NZ714502A (en) * 2011-07-05 2017-04-28 Vertex Pharma Processes and intermediates for producing azaindoles
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
CN103585126A (zh) * 2013-11-18 2014-02-19 南京艾德凯腾生物医药有限责任公司 一种托法替尼组合物及制备方法
NZ723859A (en) * 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
AU2015276857B2 (en) * 2014-06-20 2017-10-19 Vaxart, Inc. Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
KR101964546B1 (ko) * 2015-07-27 2019-04-01 유니켐 레버러토리스 리미티드 토파시티닙 경구 붕해 정제
CN108368115B (zh) * 2015-12-15 2020-01-03 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的盐
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
HRP20240112T1 (hr) * 2017-03-14 2024-04-12 Galapagos Nv Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak)
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US12447154B2 (en) * 2020-03-09 2025-10-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome
CA3222218A1 (en) * 2021-06-21 2022-12-29 Lifan TU Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235819A1 (en) * 2014-12-16 2017-10-25 Centaurus BioPharma Co., Ltd. Pyrrolopyrimidine compound
WO2017215628A1 (zh) * 2016-06-16 2017-12-21 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物

Also Published As

Publication number Publication date
CA3123985A1 (en) 2020-07-02
US20220072002A1 (en) 2022-03-10
EP3904356A1 (en) 2021-11-03
CN113242859B (zh) 2023-04-14
CN116473973A (zh) 2023-07-25
WO2020135401A1 (zh) 2020-07-02
JP2022515272A (ja) 2022-02-17
AU2019413421B2 (en) 2025-02-13
KR20210132007A (ko) 2021-11-03
JP2025032127A (ja) 2025-03-11
AU2019413421A1 (en) 2021-08-12
EP3904356A4 (en) 2022-09-21
CN113242859A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
AU2019413421B9 (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
AU2024203642B2 (en) Methods of treating Crohn's disease and ulcerative colitis
KR20230145439A (ko) Irak4 분해제 및 이의 용도
EP2818169B1 (en) Conjugate of polyethylene glycol and naloxone, pharmaceutical composition and use thereof
KR102810262B1 (ko) 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US10485788B2 (en) Pharmaceutical combinations
EP3957631B1 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma
KR20250156852A (ko) 치료적으로 활성인 화합물의 약제학적 조성물
WO2019096303A1 (zh) 一种局部给药的药物组合物及其制备方法
CN105311029A (zh) 抗肿瘤活性的喹啉衍生物
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
TW201821080A (zh) 用於治療發炎性疾病之化合物及其醫藥組合物
TW200303753A (en) Crystalline polymorphic form of irinotecan hydrochloride, a process for preparing the same, a pharmaceutical composition comprising it and its use as a therapeutic agent
JPH06234637A (ja) 腫瘍壊死因子アルファを阻害するためのレフルノミドの使用
JP2012526089A (ja) カバジタキセルおよびカペシタビンを含む抗腫瘍性組み合わせ
RU2810112C2 (ru) Лечебное применение пирролопиримидинового соединения и твердая фармацевтическая композиция пирролопиримидинового соединения
HK40063616A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
HK40055927B (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
HK40055927A (en) Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
WO2023179547A1 (zh) 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2022268075A1 (zh) 化合物在制备用于治疗骨髓纤维化及其相关症状/体征的药物中的应用、该化合物的用途
TW202245780A (zh) 用於治療神經膠質母細胞瘤之方法
JP7093764B2 (ja) 骨髄異形成症候群の治療方法

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Free format text: FORMER OWNER(S): SHOUYAO HOLDINGS (BEIJING) CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.; CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.